Potentiation of β-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 3, 1997, Pages 335-343

  Livermore, D M ^a   Chen, Han Yuan ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; IMIPENEM; MEROPENEM; MONOBACTAM; PIPERACILLIN; RO 48 1256; TAZOBACTAM; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEFTAZIDIME; DRUG SYNERGISM; ENZYME INHIBITORS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MONOBACTAMS; PENICILLANIC ACID; PIPERACILLIN; PORINS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 0030762264     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.3.335     Document Type: Article

References (18)

1. Livermore, D. M. & Yang, Y.-J. (1987). β-Lactamase lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase-inducibility mutants of Pseudomonas aeruginosa. Journal of Infectious of Diseases 155, 775-82.
2. Livermore, D.M. (1992). Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 36, 2046-8.
3. Zhou, X. Y., Kitzis, M. D. & Gutmann, L. D. (1993). Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 37, 1387-9.
4. Livermore, D. M. (1995). β-Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 8, 557-84.
5. Angehrn, P. & Gutknecht, E. M. (1995). Bridged β-lactam Ro 48-1256. Antibacterial activity in combination with cephalosporins and imipenem. In Abstract of the Thirty-Fifth Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F148, p. 138. American Society for Microbiology, Washington, DC.
6. Senda, K., Arakawa, Y., Nakashima, K., Ito, H., Ichiyama, S., Shimokata, K., Kato, N. & Ohta, M. (1996). Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrobial Agents and Chemotherapy 40, 349-53.
7. Hubschwerlen, C., Angehrn, P., Gubernator, K., Gutknecht, E.-M., Heinze-Krauss, I., Kania, M., Page, M. G. P., Sogabe, S., Specklin, J.-L. & Winkler, F. (1997). Bridged β-lactams as β-lactamase inhibitors: I. Synthesis and evaluation of bridged monobactams. Journal of Medicinal Chemistry, in press.
8. Williams, R. J., Lindridge, M. A., Said, A. A., Livermore, D. M. & Williams, J. D. (1984). National survey of antibiotic resistance in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 14, 9-16.
9. Williams, R. J., Livermore, D. M., Lindridge, M. A., Said, A. A. & Williams, J. D. (1984). Mechanisms of β-lactam resistance in British isolates of Pseudomonas aeruginosa. Journal of Medical Microbiology 17, 283-93.
10. Chen, H. Y., Yuan, M., Ibrahim-Elmagboul, I. B. & Livermore, D. M. (1995). National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 35, 521-34.
11. Chen, H. Y., Yuan, M. & Livermore, D. M. (1995). Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. Journal of Medical Microbiology 43, 300-9.
12. Danel, F., Hall, L. M., Gur, D., Akalin, H. E. & Livermore, D. M. (1995). Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa isolates. Journal of Antimicrobial Chemotherapy 35, 281-94.
13. Hall, L. M., Livermore, D. M., Gur, D., Akova, M. & Akalin, H. E. (1993). OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 37, 1637-44.
14. Danel, F., Hall, L. M., Gur, D. & Livermore, D. M. (1995). OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1881-4.
15. Livermore, D. M. & Yang, Y. J. (1989). Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterised resistance mechanisms. Journal of Antimicrobial Chemotherapy 24 Suppl. A, 149-59.
16. Chen, H. Y. & Livermore, D. M. (1994). In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. Journal of Antimicrobial Chemotherapy 33, 949-58.
17. Calandra, G., Ricci, F., Wang, C. & Brown, K. (1986). Cross-resistance and imipenem. Lancet ii, 340-1.
18. Li, X.-Z, Nikaido, H. & Poole, K. (1995). Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1948-53.